213 related articles for article (PubMed ID: 22899191)
1. Synchronous bronchioloalveolar and squamous cell lung cancer with different 18F-FDG avidity on PET/CT.
Derlin T; Clauditz TS; Quaas A; Habermann CR
Clin Nucl Med; 2012 Oct; 37(10):e255-6. PubMed ID: 22899191
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer.
Manabe O; Hattori N; Hirata K; Itoh K; Hosokawa M; Takahashi H; Oyama-Manabe N; Tamaki N
J Nucl Med; 2013 May; 54(5):670-6. PubMed ID: 23516310
[TBL] [Abstract][Full Text] [Related]
3. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose.
Balogova S; Huchet V; Kerrou K; Nataf V; Gutman F; Antoine M; Ruppert AM; Prignon A; Lavolée A; Montravers F; Mayaud C; Cadranel J; Talbot JN
Nucl Med Commun; 2010 May; 31(5):389-97. PubMed ID: 20145579
[TBL] [Abstract][Full Text] [Related]
4. Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT.
Strobel K; Haerle SK; Stoeckli SJ; Schrank M; Soyka JD; Veit-Haibach P; Hany TF
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):919-27. PubMed ID: 19205699
[TBL] [Abstract][Full Text] [Related]
5. Differential uptake of 18F-FDG in patients with synchronous lung cancers.
Navalkissoor S; Szyszko T; Rankin S; Gnanasegaran G
Ann Nucl Med; 2011 May; 25(4):299-302. PubMed ID: 21234727
[TBL] [Abstract][Full Text] [Related]
6. Localized form of bronchioloalveolar carcinoma: FDG PET findings.
Kim BT; Kim Y; Lee KS; Yoon SB; Cheon EM; Kwon OJ; Rhee CH; Han J; Shin MH
AJR Am J Roentgenol; 1998 Apr; 170(4):935-9. PubMed ID: 9530038
[TBL] [Abstract][Full Text] [Related]
7. Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma.
Raz DJ; Odisho AY; Franc BL; Jablons DM
J Thorac Cardiovasc Surg; 2006 Nov; 132(5):1189-95. PubMed ID: 17059942
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Glut-1 glucose transporter expression with.
Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
[TBL] [Abstract][Full Text] [Related]
9. A rare case of synchronous fetal type adenocarcinoma and mucinous adenocarcinoma of the lung evaluated by 18F-FDG PET/CT.
Paone G; Treglia G; Bongiovanni M; Ceriani L; Giovanella L
Clin Nucl Med; 2014 Aug; 39(8):e384-6. PubMed ID: 23877519
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma?
Yap CS; Schiepers C; Fishbein MC; Phelps ME; Czernin J
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1166-73. PubMed ID: 12192561
[TBL] [Abstract][Full Text] [Related]
11. Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer.
Suzuki H; Hasegawa Y; Terada A; Ogawa T; Hyodo I; Suzuki M; Nakashima T; Tamaki T; Nishio M
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1191-5. PubMed ID: 19015450
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers.
Sun JS; Park KJ; Sheen SS; Yoon JK; Yoon SN; Lee KB; Hwang SC
Lung Cancer; 2009 Nov; 66(2):205-10. PubMed ID: 19203812
[TBL] [Abstract][Full Text] [Related]
13. (18)F-FDG PET-detected synchronous primary neoplasms in the staging of esophageal cancer: incidence, cost, and impact on management.
Malik V; Johnston C; Donohoe C; Claxton Z; Lucey J; Ravi N; Reynolds JV
Clin Nucl Med; 2012 Dec; 37(12):1152-8. PubMed ID: 23154472
[TBL] [Abstract][Full Text] [Related]
14. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules.
Higashi K; Ueda Y; Sakuma T; Seki H; Oguchi M; Taniguchi M; Taki S; Tonami H; Katsuda S; Yamamoto I
J Nucl Med; 2001 Oct; 42(10):1489-96. PubMed ID: 11585862
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity?
Kim TJ; Park CM; Goo JM; Lee KW
AJR Am J Roentgenol; 2012 Jan; 198(1):83-8. PubMed ID: 22194482
[TBL] [Abstract][Full Text] [Related]
16. Lobar mucinous bronchioloalveolar carcinoma of the lung showing negative FDG uptake on integrated PET/CT.
Sung YM; Lee KS; Kim BT; Han J; Lee EJ
Eur Radiol; 2005 Oct; 15(10):2075-8. PubMed ID: 15717197
[TBL] [Abstract][Full Text] [Related]
17. Superscan-like hypermetabolic lesions on delayed FDG PET/CT imaging in a patient with lung cancer.
Cheng G; Alavi A; Lim E; Akers SR
Clin Nucl Med; 2012 Sep; 37(9):912-3. PubMed ID: 22889790
[TBL] [Abstract][Full Text] [Related]
18. Collision lung cancer on F-18 FDG PET/CT.
Sato M; Abe T; Ito Y; Koyama K; Hayashi Y
Clin Nucl Med; 2011 Aug; 36(8):e98-100. PubMed ID: 21716011
[TBL] [Abstract][Full Text] [Related]
19. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
Bryant AS; Cerfolio RJ
Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT demonstrating response to targeted therapy in synchronous metastatic adenocarcinoma of the lung and poorly differentiated carcinoma of the thyroid.
Kumar NS; Basu S
Natl Med J India; 2015; 28(3):155. PubMed ID: 26724353
[No Abstract] [Full Text] [Related]
[Next] [New Search]
